战略合作 | 康瑞佰欧与三优生物达成生物标志物试剂盒开发战略合作

战略合作

中国上海·浙江温州 2025年12月10日——温州康瑞佰欧生物技术有限公司（以下简称“康瑞佰欧”）与三优生物医药（上海）有限公司（以下简称“三优生物”）共同宣布，双方正式签署战略合作协议。此次合作将聚焦于生物标志物试剂盒关键试剂及产品的联合开发，旨在整合双方在创新生物药源头发现与试剂盒产品矩阵研发生产领域的核心优势，共同为全球生物医药研发客户提供更高效、更精准、更可靠的生物标志物检测整体解决方案，加速药物研发与伴随诊断进程。

生物标志物在药物研发、临床诊断及个性化医疗中扮演着越来越关键的角色。本次战略合作基于双方对行业趋势的深刻洞察与彼此技术实力的高度认可。康瑞佰欧则将依托其在高端分析仪器、高值耗材及试剂盒产品开发方面的深厚积淀，以及符合国际标准的生产与质量管控体系，确保合作产品的规模化生产、性能验证与稳定供应。三优生物将凭借其全球领先的智能超万亿分子库（AI-STAL） 及一体化药物发现平台，为针对特定生物标志物的高性能抗体等关键试剂的发现与优化提供源头创新动力。

本次战略合作旨在通过深度协同，在多个层面创造核心价值：

1. 加速研发进程：通过联合开发，缩短高性能生物标志物检测试剂从发现到产品化的周期，助力药企更快地进行患者分层、药效评估和伴随诊断开发。

2. 提升产品竞争力：结合三优生物的源头创新优势和康瑞佰欧的工程化及成本控制能力，共同打造性能更优异、供应更稳定、性价比更高的国产高端试剂盒产品，打破部分领域对进口产品的依赖。

3. 开拓市场新局：双方将整合市场资源，共同推广合作开发的试剂盒产品及解决方案，为国内外生物药企、CRO及诊断公司提供更优质的选择，携手开拓广阔的精准医疗市场。

康瑞佰欧创始人、董事长兼CEO邹灵龙博士表示：“我们非常高兴能与三优生物达成战略合作。三优生物在超大库容分子库和智能化筛选方面的卓越能力，令人印象深刻。此次合作将使康瑞佰欧在试剂盒产品开发的‘上游’获得强大的创新引擎支持。我们相信，双方‘发现+转化’的深度融合，能够快速响应市场需求，开发出真正解决客户痛点的、高质量的生物标志物检测产品，共同推动行业技术进步。”

三优生物创始人兼CEO郎国竣博士表示：“与康瑞佰欧的合作，是三优生物‘让天下没有难做的创新生物药’使命在精准诊断领域的重要延伸。康瑞佰欧在试剂盒产品系统化开发与生产方面的‘硬实力’有目共睹。本次战略协同，是将我们的分子发现能力与产业伙伴的工程化平台进行深度链接的关键一步。我们期待通过这次合作，不仅能输出优质的关键试剂，更能参与到最终解决客户检测难题的产品创造中，为生物医药研发提供更坚实的工具支撑，共同赋能产业链的升级。”

本次战略合作标志着康瑞佰欧与三优生物在深化产业协同、构建核心技术壁垒方面迈出了坚实一步。双方将以此次合作为起点，持续探索更广阔的合作空间，致力于成为全球生物医药研发企业值得信赖的合作伙伴。

Shanghai, China & Wenzhou, Zhejiang – December 10, 2025 – Wenzhou KanryBio Biotech Co., Ltd. (“KanryBio”) and Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (“Sanyou Bio”) today announced a strategic collaboration agreement. The partnership will focus on the joint development of key reagents and products for biomarker assay kits. By integrating Sanyou Bio's core strengths in innovative biologics discovery with KanryBio's expertise in kit product development and manufacturing, the collaboration aims to provide global biopharmaceutical R&D clients with more efficient, precise, and reliable total solutions for biomarker detection, thereby accelerating drug development and companion diagnostic processes.

Biomarkers are playing an increasingly critical role in drug R&D, clinical diagnostics, and personalized medicine. This strategic partnership is built upon both parties' deep understanding of industry trends and mutual recognition of each other's technical prowess. KanryBio will contribute its extensive experience in high-end analytical instruments, high-value consumables, and kit development, along with its international-standard production and quality control systems, to ensure scalable manufacturing, performance validation, and stable supply of the co-developed products. Sanyou Bio will leverage its globally leading AI Super-Trillion-Level (AI-STAL) intelligent molecular library and integrated drug discovery platform to drive innovative discovery and optimization of high-performance antibodies and other key reagents targeting specific biomarkers. 

Through deep synergy, this collaboration aims to create core value across multiple dimensions:

1. Accelerated R&D Cycles: Joint development will shorten the timeline from discovery to productization of high-performance biomarker detection reagents, helping pharmaceutical companies expedite patient stratification, efficacy evaluation, and companion diagnostic development.

2. Enhanced Product Competitiveness: Combining Sanyou Bio's source innovation with KanryBio's engineering and cost-control capabilities, the partners will create high-end, domestically produced assay kits with superior performance, stable supply, and higher cost-effectiveness, reducing dependence on imported products in certain fields.

3. New Market Expansion: By pooling market resources, both companies will jointly promote the co-developed kit products and solutions, offering superior options to biopharmaceutical companies, CROs, and diagnostic firms worldwide and jointly exploring the vast precision medicine market.

Dr. Linglong Zou, Chairman and CEO of KanryBio, stated: "We are thrilled to partner with Sanyou Bio. Their exceptional capabilities in ultra-large-capacity molecular libraries and intelligent screening are impressive. This collaboration provides KanryBio with a powerful innovation engine for the 'upstream' of kit product development. We believe the deep integration of 'discovery + translation' will enable us to respond rapidly to market needs and develop high-quality biomarker detection products that address real customer pain points, jointly advancing industry technology."

Dr. Guojun Lang, Founder and CEO of Sanyou Bio, commented: "The collaboration with KanryBio is a significant extension of Sanyou Bio's mission—'to make innovative biologics accessible to all'—into the field of precision diagnostics. KanryBio's proven 'hard strength' in systematic kit development and production is widely recognized. This strategic synergy is a key step in connecting our molecular discovery capabilities with an industrial partner's engineering platform. We expect this partnership will not only supply high-quality key reagents but also enable us to participate in creating final products that solve customer detection challenges, providing more robust tools for biopharmaceutical R&D and jointly empowering the upgrade of the industry chain."

This strategic partnership marks a solid step for KanryBio and Sanyou Bio in deepening industrial collaboration and building core technological advantages. Both parties will use this collaboration as a starting point to continuously explore broader cooperation, striving to become trusted partners for global biopharmaceutical R&D enterprises.

关于三优生物

三优生物是一家以“让天下没有难做的创新生物药”为使命，以超万亿分子库和智能科技驱动的生物医药高科技企业。公司致力于打造全球顶尖的原创新药创新工场。公司以智能超万亿分子库（AI-STAL）为核心；以干湿结合、国际领先的创新生物药智能化及一体化研发平台为依托；以多样化的业务模式推动全球创新药物的研发及产业化。公司总部位于中国上海，在亚洲、北美洲、欧洲等多地建立了业务中心，形成了全球化的业务网络，现有投产及布局的研发及GMP场地20,000多平方米。公司已与全球2,000多家药企、生技公司等建立了良好的合作关系，已赋能1200多个新药研发项目；已完成50多个合作研发项目，其中10多个协同研发项目已推至IND及临床研发阶段。公司已申请130多项发明专利，其中30多项发明专利已获得授权，并获得了国家级高新技术企业、上海市专精特新、ISO9001、ISO27001等10余项资质及体系认证。

关于康瑞佰欧

温州康瑞佰欧生物技术有限公司（以下简称“康瑞佰欧”）由顶尖生物分析专家创立，依托国科温州研究院雄厚的科研与技术实力，秉承“让天下没有难做的分析方法”初衷，专注于高端分析仪器、高值耗材以及试剂的研发、生产与销售，旨在打造高度自动化、高灵敏度分析检测的解决方案。成立以来，公司通过不断的技术创新和产品升级，已累积多款性能优良的特色产品，涵盖分析实验室所需的仪器设备、高端耗材与试剂，致力成为生物分析实验室的一站式产品提供商。总部设立于浙江温州的研发中心是康瑞佰欧的创新引擎，汇聚了行业内的专业人才和先进的研发与生产设备，生产车间顺利通过ISO9001质量管理体系认证。康瑞佰欧聚焦电化学发光分析平台、细胞分选平台、智能实验室自动化平台、智能健康检测产品的开发，旨在破除行业痛点，成为赋能生物医药研发、医疗服务行业相关领域的全球知名企业。

成立以来，康瑞佰欧已获评2022年温州市「全球精英创新创业大赛总决赛一等奖」、2023年北京市「国科大杯创新创业大赛分项赛一等奖、总决赛二等奖」、2023年温州市龙湾区、2024年温州市「领军型人才创业项目」、2025年入选浙江省「顶尖人才 创业项目」、2025年入选浙江省「科技型中小企业」。

更多信息，请访问康瑞佰欧官方网站：
www.kanrybio.com